{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:39:46Z","timestamp":1777433986325,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["23390221"],"award-info":[{"award-number":["23390221"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["23B-30"],"award-info":[{"award-number":["23B-30"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["24591182"],"award-info":[{"award-number":["24591182"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009158","name":"Kawasaki Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009158","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.yexcr.2014.04.012","type":"journal-article","created":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T09:15:13Z","timestamp":1398417313000},"page":"201-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors"],"prefix":"10.1016","volume":"326","author":[{"given":"Masayuki","family":"Yasugi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagio","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadoaki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daijiro","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsune","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2014.04.012_bib1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","article-title":"The biology and treatment of EML4-ALK non-small cell lung cancer","volume":"46","author":"Sasaki","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.yexcr.2014.04.012_bib2","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1200\/JCO.2010.29.6038","article-title":"Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases","volume":"28","author":"Sun","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2014.04.012_bib3","article-title":"Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement","author":"Kim","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.yexcr.2014.04.012_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE trial: personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.yexcr.2014.04.012_bib5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2012.45.3753","article-title":"Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies","volume":"31","author":"Li","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2014.04.012_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1349-7006.2007.00607.x","article-title":"Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer","volume":"98","author":"Mitsudomi","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.yexcr.2014.04.012_bib7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2014.04.012_bib8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2014.04.012_bib9","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2014.04.012_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2014.04.012_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2014.04.012_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-010-9201-z","article-title":"Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy","volume":"29","author":"Gazdar","year":"2010","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.yexcr.2014.04.012_bib13","first-page":"456","article-title":"Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors","volume":"37","author":"Giaccone","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.yexcr.2014.04.012_bib14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2012.43.3912","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease","volume":"31","author":"Ohashi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2014.04.012_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2011.06.012","article-title":"Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study","volume":"75","author":"Gately","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.yexcr.2014.04.012_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1634\/theoncologist.2007-0171","article-title":"The potential role of mTOR inhibitors in non-small cell lung cancer","volume":"13","author":"Gridelli","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.yexcr.2014.04.012_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI44145","article-title":"Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy","volume":"121","author":"Wander","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yexcr.2014.04.012_bib18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","article-title":"Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells","volume":"64","author":"Boulay","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2014.04.012_bib19","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1158\/0008-5472.CAN-07-0681","article-title":"Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line","volume":"67","author":"Ogino","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2014.04.012_bib20","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/0008-5472.CAN-08-4205","article-title":"Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice","volume":"69","author":"Ohashi","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2014.04.012_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.yexcr.2014.04.012_bib22","first-page":"129","article-title":"Comparison of chemosensitivity tests: clonogenic assay versus MTT assay","volume":"56","author":"Kawada","year":"2002","journal-title":"Acta Med. Okayama"},{"key":"10.1016\/j.yexcr.2014.04.012_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.yexcr.2014.04.012_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2014.04.012_bib25","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2014.04.012_bib26","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJMra0901217","article-title":"Cell death","volume":"361","author":"Hotchkiss","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2014.04.012_bib27","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1158\/1078-0432.CCR-10-0480","article-title":"Target of rapamycin signaling in leukemia and lymphoma","volume":"16","author":"Vu","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2014.04.012_bib28","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1158\/0008-5472.CAN-10-4475","article-title":"Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1","volume":"71","author":"Li","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2014.04.012_bib29","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1038\/sj.onc.1209888","article-title":"mTOR, translation initiation and cancer","volume":"25","author":"Mamane","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2014.04.012_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.cdd.4400978","article-title":"Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic","volume":"9","author":"Castedo","year":"2002","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.yexcr.2014.04.012_bib31","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1158\/1078-0432.CCR-09-0099","article-title":"High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma","volume":"15","author":"Anagnostou","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2014.04.012_bib32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/1078-0432.CCR-09-0986","article-title":"Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer","volume":"16","author":"Yoshizawa","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2014.04.012_bib33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/JTO.0b013e3181ce6604","article-title":"Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer","volume":"5","author":"Dhillon","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.yexcr.2014.04.012_bib34","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1002\/cncr.25959","article-title":"Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma","volume":"117","author":"Liu","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.yexcr.2014.04.012_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.yexcr.2014.04.012_bib36","doi-asserted-by":"crossref","first-page":"e18691","DOI":"10.1371\/journal.pone.0018691","article-title":"EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells","volume":"6","author":"Han","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2014.04.012_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2013.05.012","article-title":"Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer","author":"Li","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.yexcr.2014.04.012_bib38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJMra1205406","article-title":"Autophagy in human health and disease","volume":"368","author":"Choi","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2014.04.012_bib39","doi-asserted-by":"crossref","first-page":"e62104","DOI":"10.1371\/journal.pone.0062104","article-title":"mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF","volume":"8","author":"Ishikawa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2014.04.012_bib40","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","article-title":"Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors","volume":"5","author":"Buck","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.yexcr.2014.04.012_bib41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bcp.2009.04.033","article-title":"Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines","volume":"78","author":"La Monica","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yexcr.2014.04.012_bib42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00280-012-1946-3","article-title":"Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"70","author":"Dong","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.yexcr.2014.04.012_bib43","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","article-title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors","volume":"20","author":"Soria","year":"2009","journal-title":"Ann. Oncol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482714001700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482714001700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:16:36Z","timestamp":1757996196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482714001700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0014482714001700"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2014.04.012","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2014.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}